Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum.
Lymphocyte sensitivity to encephalitogenic factor (EF) was measured with the macrophage migration inhibition (MMI) test in 60 women with dysplasia or carcinoma in situ of the cervix, in 10 women with invasive cervical carcinoma, and in 20 women with a variety of benign gynaecological conditions. Significant migration inhibition with EF (P less than 0.01) was seen with lymphocytes taken from 7/13 (54%) women with mild and/or moderate dysplasia, from 22/47 (47%) women with severe dysplasia and/or carcinoma in situ, from 6/10 (60%) women with invasive cervical carcinoma and from 3/20 (15%) women with benign gynaecological conditions. Autologous serum was seen to abrogate EF-mediated migration inhibition in 3/4 sensitized women with mild and/or moderate dysplasia, in 5/7 sensitized women with severe dysplasia and/or csrcinoma in situ and in 2/3 sensitized women with invasive cervical carcinoma. Autologous serum from 2 sensitized women with benign gynaecological conditions did not abrogate the response of their lymphocytes to EF.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001769:Blood; D002464:Cell Migration Inhibition; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008264:Macrophages / Q000276:immunology; D008875:Middle Aged; D004676:Myelin Basic Protein / Q000276:immunology*; D002578:Uterine Cervical Dysplasia / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology*
D004676:Myelin Basic Protein